Subsidiary of Shenzhen Kangtai Biological Products (300601.SZ) received the summary report of Phase I/III clinical trials of adsorbed tetanus vaccine.

Shenzhen Kangtai Biological Products (300601.SZ) announced that its wholly-owned subsidiary Beijing Minhai Biological Technology Co., Ltd. ("Minhai Biological") recently received the summary report of the phase I/III clinical trial of its adsorbed tetanus vaccine. The clinical research stage of Minhai Biological's developed adsorbed tetanus vaccine has been successfully completed. The research results show that the adsorbed tetanus vaccine developed by Minhai Biological has good safety and immunogenicity when used for adult immunization. The acquisition of the summary report of the phase I/III clinical trial of the adsorbed tetanus vaccine indicates that it meets the necessary conditions for production application.